What is the clinical significance of a hematocrit of 36.8%?

Clinical Significance of Hematocrit 36.8%

A hematocrit of 36.8% falls within the normal physiological range and generally does not require intervention in most clinical contexts. This value sits at the lower boundary of normal ranges established in healthy populations and is well above thresholds that trigger transfusion or aggressive management in critical care settings.

Context-Dependent Interpretation

In Healthy/Athletic Populations

• 36.8% represents the lower limit of the normal range for healthy individuals, as demonstrated in professional athletes where the physiological range spans 36.8-47.8% 1
• Athletes with hematocrit values in this range (lowest quintile, <40%) actually demonstrated superior aerobic capacity and performance markers compared to those with higher values 1
• This "training-induced autohemodilution" is a normal physiological adaptation and should not be pathologized

In Critical Care/Hospitalized Patients

• Current guidelines recommend restrictive transfusion strategies with hemoglobin thresholds of 7.0-8.0 g/dL (corresponding to hematocrit ~21-24%), not 36.8% 2, 3
• A hematocrit of 36.8% is well above any transfusion threshold and requires no blood product administration
• High-quality evidence shows that maintaining hemoglobin 10.0-12.0 g/dL (hematocrit ~30-36%) provides optimal outcomes without increased mortality 2

In Dialysis/Chronic Kidney Disease

• The 36.8% value falls within the optimal target range of 33-36% established by multiple large epidemiological studies 4, 5, 6, 7
• Patients with sustained hematocrit 33-36% demonstrate:
  • 7% reduced risk of death compared to those with 30-33% 7
  • 16-22% lower hospitalization rates compared to lower values 4
  • 8.3-8.5% lower Medicare expenditures 4, 5
• Targeting higher values (>36%) in patients with cardiovascular disease may paradoxically increase mortality 2

Clinical Action Points

No intervention is needed for hematocrit 36.8% unless:

1. Acute decline is documented - A dropping hematocrit trend (even within normal range) predicts ICU admission and longer hospital stays in trauma 8 and indicates ongoing bleeding requiring source control

2. Severe sepsis is present - Low-normal hematocrit in septic patients carries increased 30-day mortality risk (58.9% increase) 9, though this reflects disease severity rather than need for transfusion

3. Symptomatic anemia exists - Evaluate for:

   • Iron deficiency (ferritin <100 mg/L, transferrin saturation <20%)
   • B12/folate deficiency
   • Chronic disease/inflammation
   • Occult blood loss

Key Pitfalls to Avoid

• Do not transfuse based on arbitrary numbers - Modern evidence strongly supports restrictive strategies; transfusion at hematocrit 36.8% would be inappropriate and potentially harmful 10
• Do not ignore the trend - A stable 36.8% is benign; a falling 36.8% (from 42% yesterday) demands investigation 8
• Do not apply dialysis targets to other populations - The 33-36% target is specific to chronic kidney disease patients on erythropoietin therapy 2
• Do not use erythropoiesis-stimulating agents in critical care except when combined with iron for specific indications, as they increase thrombotic risk without mortality benefit 2

Bottom Line

Hematocrit 36.8% is physiologically normal and requires no treatment in isolation. Focus clinical attention on the underlying cause if this represents a decline, the presence of symptoms, or specific comorbidities (particularly chronic kidney disease or active sepsis) rather than the number itself. The restrictive transfusion approach supported by high-quality evidence 10 means this value is nowhere near requiring blood products.